Analytical Data
-
Gene name
MYD88
- Application
-
Alternative Names
Mutant myeloid differentiation primary response 88; MYD 88; Myd88; MYD88_HUMAN; MYD88D; Myeloid differentiation marker 88; Myeloid differentiation primary response 88; Myeloid differentiation primary response gene (88); Myeloid differentiation primary response gene 88; Myeloid differentiation primary response gene; Myeloid differentiation primary response protein MyD88; OTTHUMP00000161718; OTTHUMP00000208595; OTTHUMP00000209058; OTTHUMP00000209059; OTTHUMP00000209060
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99836
-
Expression Region
1-296aa
-
Molecular Weight
37.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYD88 (myeloid differentiation primary response gene 88) is a critical adaptor protein involved in immune signaling pathways, particularly those activated by Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). Its central role in the innate immune response has garnered significant attention, as mutations or dysregulation of MYD88 are associated with various diseases, especially certain hematological malignancies like Waldenström macroglobulinemia and diffuse large B-cell lymphoma. These mutations often lead to constitutive activation of downstream signaling pathways, resulting in enhanced survival and proliferation of malignant cells. Studies have increasingly focused on MYD88's structure and function, aiming to uncover the molecular mechanisms underlying its role in immune responses and cancer. Investigating the recombinant expression of MYD88 protein allows for detailed analysis of its interactions with various ligands and downstream signaling molecules. By studying MYD88 in a controlled setting, researchers hope to elucidate its function in both healthy and diseased states and to identify potential therapeutic targets. As a result, MYD88 has emerged as a focal point in both immunology and oncology research, with promising implications for the development of targeted therapies that could disrupt its aberrant signaling in disease contexts.
